TW561150B - Inorganic ion receptor-modulating compounds and pharmaceutical composition comprising them - Google Patents

Inorganic ion receptor-modulating compounds and pharmaceutical composition comprising them Download PDF

Info

Publication number
TW561150B
TW561150B TW086105804A TW86105804A TW561150B TW 561150 B TW561150 B TW 561150B TW 086105804 A TW086105804 A TW 086105804A TW 86105804 A TW86105804 A TW 86105804A TW 561150 B TW561150 B TW 561150B
Authority
TW
Taiwan
Prior art keywords
cells
item
scope
patent application
compound according
Prior art date
Application number
TW086105804A
Other languages
English (en)
Chinese (zh)
Inventor
Scott T Moe
Wagenen Bradford C Van
Eric G Delmar
Richard Trovato
Manuel F Balandrin
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of TW561150B publication Critical patent/TW561150B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Prostheses (AREA)
  • Steroid Compounds (AREA)
TW086105804A 1996-05-01 1997-05-01 Inorganic ion receptor-modulating compounds and pharmaceutical composition comprising them TW561150B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1667396P 1996-05-01 1996-05-01

Publications (1)

Publication Number Publication Date
TW561150B true TW561150B (en) 2003-11-11

Family

ID=21778338

Family Applications (1)

Application Number Title Priority Date Filing Date
TW086105804A TW561150B (en) 1996-05-01 1997-05-01 Inorganic ion receptor-modulating compounds and pharmaceutical composition comprising them

Country Status (11)

Country Link
US (3) US5981599A (enExample)
EP (1) EP0907631B1 (enExample)
JP (2) JP4117506B2 (enExample)
AT (3) ATE243186T1 (enExample)
AU (1) AU731146C (enExample)
DE (3) DE69739388D1 (enExample)
DK (1) DK0907631T3 (enExample)
ES (3) ES2280460T3 (enExample)
PT (1) PT907631E (enExample)
TW (1) TW561150B (enExample)
WO (1) WO1997041090A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
WO1997041090A1 (en) * 1996-05-01 1997-11-06 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
US6362231B1 (en) * 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
CN1269782A (zh) * 1997-07-09 2000-10-11 阿克佐诺贝尔公司 螯合试剂以及它们的锰螯合物
WO1999024022A2 (en) * 1997-11-10 1999-05-20 F. Hoffmann-La Roche Ag Isoquinoline derivatives for treating disorders associated with 5ht7 receptors
FR2800735B1 (fr) * 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
US7176243B2 (en) * 2000-06-02 2007-02-13 The General Hospital Corporation CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
FR2812875B1 (fr) * 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6475792B1 (en) 2000-10-12 2002-11-05 Marical, Llc Methods for raising pre-adult anadromous fish
US6951739B2 (en) 2000-10-12 2005-10-04 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
US6463882B1 (en) * 2000-10-12 2002-10-15 Marical, Llc Growing marine fish in freshwater
US7101988B2 (en) * 2000-10-12 2006-09-05 Marical, Inc. Polyvalent cation-sensing receptor in Atlantic salmon
US6979559B2 (en) * 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
US6979558B2 (en) * 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in Atlantic salmon
US6481379B1 (en) 2000-10-12 2002-11-19 Marical, Llc Methods for raising pre-adult anadromous fish
US6564747B2 (en) * 2000-10-12 2003-05-20 Marical, Llc Methods for raising pre-adult anadromous fish
US6463883B1 (en) * 2000-10-12 2002-10-15 Marical, Llc Methods for raising pre-adult anadromous fish
ATE322159T1 (de) * 2001-10-11 2006-04-15 Marical Inc Verfahren zum züchten und imprimieren von fischen mittels eines geruchstoffes
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
PT1663182E (pt) 2003-09-12 2013-03-14 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
EG23529A (en) * 2003-11-05 2006-04-11 Amri Moosa E Al System and method to broadcast the video or tv anddisplaying on pc tv by choosing the required prog ram from the internet
WO2005065050A2 (ja) 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
PL1757582T3 (pl) 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
JP2008533170A (ja) * 2005-03-17 2008-08-21 アムジエン・インコーポレーテツド 石灰化減少方法
PL1882684T3 (pl) * 2005-05-19 2015-08-31 Astellas Pharma Inc Pochodna pirolidyny albo jej sól
CA2606099A1 (en) * 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
JP5309014B2 (ja) * 2006-03-23 2013-10-09 アムジエン・インコーポレーテツド シナカルセットの多形体の製造および使用のための方法および組成物
US8779004B2 (en) 2006-04-20 2014-07-15 Amgen, Inc. Stable emulsion formulations
US8093299B2 (en) 2007-03-30 2012-01-10 Amgen Inc. Methods of treating bowel disorders
WO2008139947A1 (ja) * 2007-05-08 2008-11-20 Ajinomoto Co., Inc. 下痢の予防又は治療剤
EP2212284B1 (en) * 2007-10-15 2014-04-30 Amgen Inc. Calcium receptor modulating agents
WO2010010359A2 (en) * 2008-07-24 2010-01-28 Cilpa Limited A process for the preparation of cinacalcet and its salts
WO2010042642A1 (en) * 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
CA2762130A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
US20120101039A1 (en) * 2009-05-27 2012-04-26 Leo Pharma A/S Calcium-sensing receptor-active compounds
CA2762137A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
CN102958907A (zh) 2010-06-30 2013-03-06 利奥制药有限公司 钙敏感受体激动化合物的新多晶型
JP5968881B2 (ja) 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
CN103270018A (zh) 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
JP2014508104A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
JP2014507375A (ja) 2010-11-26 2014-03-27 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
EP2643298A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
US9382216B2 (en) 2011-03-10 2016-07-05 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
WO2013136288A1 (en) * 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2276618A (en) * 1942-03-17 N-phenylaliphatic bihxdroxithenyl-
CH217009A (fr) * 1940-10-25 1941-09-30 Anonyme Taubert Freres Societe Boîte de montre.
US2930731A (en) * 1952-04-08 1960-03-29 Upjohn Co Bis[beta-(ortho-hydrocarbonoxyphenyl)iso-propyl]amines
BE570596A (enExample) * 1957-08-26
NL281782A (enExample) * 1961-08-14
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
NL293886A (enExample) * 1962-06-19 1965-04-12 Merck Ag E
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3459767A (en) * 1965-08-10 1969-08-05 Pfizer & Co C Aminomethylindoles
GB1109924A (en) * 1965-11-29 1968-04-18 Roche Products Ltd Novel substituted diphenylalkyl amines and a process for the manufacture thereof
DE1618005A1 (de) * 1966-09-22 1971-09-09 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen
CH480791A (de) * 1967-01-17 1969-11-15 Ciba Geigy Schädlingsbekämpfungsmittel
GB1263987A (en) * 1969-05-30 1972-02-16 Allen & Hanburys Ltd Phenethylamine derivatives
GB1448437A (en) * 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US4000197A (en) * 1973-07-23 1976-12-28 The University Of Iowa Research Foundation Asymmetric synthesis of phenylisopropylamines
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (enExample) * 1974-03-08 1982-06-04
US4014937A (en) * 1974-08-26 1977-03-29 Pfizer Inc. 3,4-And 3,5-dialkoxyphenethylamines
HU169507B (enExample) * 1974-09-25 1976-12-28
US3987201A (en) * 1974-12-24 1976-10-19 Eli Lilly And Company Method for treating arrhythmia
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
JPS5390272A (en) * 1977-01-13 1978-08-08 Sendai Fukusokan Kagaku Kenkiy Method of producing optically active salsolizine
US4608391A (en) * 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
US4289787A (en) * 1977-12-19 1981-09-15 Eli Lilly And Company Quaternary ammonium antiarrhythmic drugs
DD144050A5 (de) * 1978-06-05 1980-09-24 Ciba Geigy Ag Verfahren zur herstellung von n-alkylierten aminoalkoholen
DE2825961A1 (de) * 1978-06-14 1980-01-03 Basf Ag Fungizide amine
US4391826A (en) * 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
DK268779A (da) * 1978-07-03 1980-01-04 Lilly Co Eli Fremgangsmaade til fremstilling af phenethanolaminer
ZA794872B (en) * 1978-09-20 1980-11-26 Schering Corp A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it
FR2436773A1 (fr) * 1978-09-22 1980-04-18 Roussel Uclaf Nouveaux derives du 3-(aminoethyl) phenol et leurs sels, procede de preparation et application a titre de medicaments
US4360511A (en) * 1978-11-29 1982-11-23 Medi-Physics, Inc. Amines useful as brain imaging agents
DD150456A5 (de) * 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
EP0023385B1 (en) * 1979-06-16 1982-12-15 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
JPS603387B2 (ja) * 1980-07-10 1985-01-28 住友化学工業株式会社 新規光学活性イミダゾリジン−２−オン誘導体およびその製法
HU183430B (en) * 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
US4591605A (en) * 1981-11-10 1986-05-27 Research Foundation Of State University Of New York Method and ingestible formulation for inhibiting the secretion of stomach acid
US4658060A (en) * 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
DE3225879A1 (de) * 1982-07-10 1984-01-12 Basf Ag, 6700 Ludwigshafen Trans-3-(4'-tert.-butylcyclohexyl-1')-2-methyl-1-dialkyl-aminopropane, ihre herstellung und verwendung als arzneimittel
CA1258454A (en) * 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
US4647446A (en) * 1982-08-18 1987-03-03 The Regents Of The University Of California Rapid brain scanning radiopharmaceutical
JPS5950358A (ja) * 1982-09-14 1984-03-23 Sumitomo Chem Co Ltd 光学活性なカルボン酸をグラフトしたクロマトグラフ充填剤およびそれを用いる鏡像体混合物の分離法
US4677101A (en) * 1983-09-26 1987-06-30 Merck & Co., Inc. Substituted dihydroazepines useful as calcium channel blockers
US4661635A (en) * 1983-11-21 1987-04-28 Mcneilab, Inc. Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives
US5334628A (en) * 1984-06-09 1994-08-02 Kaken Pharmaceutical Co., Ltd. Amine derivatives, processes for preparing the same and fungicides containing the same
US4587253A (en) * 1984-07-30 1986-05-06 Merck & Co., Inc. Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4609494A (en) * 1985-02-21 1986-09-02 Merck & Co., Inc. 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8522186D0 (en) * 1985-09-06 1985-10-09 Erba Farmitalia Cycloalkyl-substituted 4-aminophenyl derivatives
DE3541181A1 (de) * 1985-11-21 1987-05-27 Basf Ag Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US4675321A (en) * 1986-02-07 1987-06-23 Merck & Co., Inc. Substituted pyrimidines useful as calcium channel blockers
US5034514A (en) * 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4808718A (en) * 1986-05-06 1989-02-28 Merck & Co., Inc. Fused polycyclic and bridged compounds useful as calcium channel blockers
HU200591B (en) * 1986-07-11 1990-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
US4797411A (en) * 1986-07-18 1989-01-10 Farmitalia Carlo Erba S.P.A. Cycloalkyl-substituted 4-pyridyl derivatives and use as aromatase inhibitors
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
DE3782010T2 (de) * 1986-12-04 1993-02-18 Toyo Jozo Kk Vom calcitonin-gen abgeleitete peptidderivate.
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US4916145A (en) * 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
EP0348490B1 (en) * 1988-01-11 1995-09-27 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5001251A (en) * 1988-01-15 1991-03-19 E. R. Squibb & Sons, Inc. Optical resolution of DL-3-acylthio-2-methylpropanoic acid
ATE139542T1 (de) * 1988-04-04 1996-07-15 Salk Inst Biotech Ind Calciumkanal-zusammensetzungen und verfahren
US5082837A (en) * 1988-06-28 1992-01-21 Merrell Dow Pharmaceuticals Lactamimides as calcium antagonists
US4925873A (en) * 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists
JPH02200658A (ja) * 1989-01-28 1990-08-08 Kumiai Chem Ind Co Ltd Ｎ―（置換）ベンジルカルボン酸アミド誘導体及び除草剤
US5011834A (en) * 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
IL94963A0 (en) * 1989-07-03 1991-06-10 Univ New York Use of polyamines as ionic-channel regulating agents
GB8915712D0 (en) * 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
US5021599A (en) * 1989-08-31 1991-06-04 Serpentix Conveyor Corporation Redox-responsive anion receptors
US5053337A (en) * 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
CA2071897A1 (en) * 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
JP2818958B2 (ja) * 1990-02-23 1998-10-30 塩野義製薬株式会社 ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
AU8876591A (en) * 1990-11-02 1992-05-26 Upjohn Company, The Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
US5403861A (en) * 1991-02-08 1995-04-04 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
DE69206306T2 (de) * 1991-04-08 1996-06-13 Sumitomo Chemical Co Optisch aktive Sekundär-Aminverbindung, Verfahren zur Herstellung einer optisch aktiven Sekundär-Aminverbindung und Verfahren zur Herstellung optisch aktiver Carbonsäure durch die Verwendung dieser Verbindung.
CN1065857A (zh) * 1991-04-16 1992-11-04 北京农业大学 光活性1,1′-联萘-2,2′-二酚的合成方法
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
AU702629B2 (en) * 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
DE69233572T2 (de) * 1991-08-23 2006-08-31 NPS Pharmaceuticals, Inc., Salt Lake City Screening-Verfahren für Kalzium-Rezeptor aktive Verbindungen
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ATE161821T1 (de) * 1991-11-12 1998-01-15 Pfizer Azyklische ethylendiaminderivate als 'substance p rezeptor' antagonisten
CA2125676A1 (en) * 1991-12-30 1993-07-08 Marcel August Constant Janssen .alpha.-substituted benzenemethanamine derivatives
AU3588693A (en) * 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
WO1994018959A1 (en) * 1993-02-23 1994-09-01 Brigham And Women's Hospital, Inc. Calcium receptor-active molecules
JP2964639B2 (ja) * 1993-05-19 1999-10-18 東レ株式会社 混繊複合仮撚糸およびその製造方法ならびにその糸を用いてなる編織物
US5504253A (en) * 1994-07-15 1996-04-02 Nps Pharmaceuticals, Inc. Amine preparation
CZ290670B6 (cs) * 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
WO1997041090A1 (en) * 1996-05-01 1997-11-06 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds

Also Published As

Publication number Publication date
ATE243186T1 (de) 2003-07-15
US20030008876A1 (en) 2003-01-09
EP0907631B1 (en) 2003-06-18
DE69739388D1 (de) 2009-06-10
AU731146B2 (en) 2001-03-22
ATE352537T1 (de) 2007-02-15
US5981599A (en) 1999-11-09
JP2000509395A (ja) 2000-07-25
JP4431609B2 (ja) 2010-03-17
ES2201300T3 (es) 2004-03-16
US6342532B1 (en) 2002-01-29
DE69722934T2 (de) 2004-05-27
AU2822997A (en) 1997-11-19
WO1997041090A1 (en) 1997-11-06
HK1102806A1 (en) 2007-12-07
US6710088B2 (en) 2004-03-23
ATE430123T1 (de) 2009-05-15
DE69722934D1 (de) 2003-07-24
HK1051995A1 (en) 2003-08-29
DE69737303D1 (de) 2007-03-15
EP0907631A1 (en) 1999-04-14
ES2280460T3 (es) 2007-09-16
JP4117506B2 (ja) 2008-07-16
DE69737303T2 (de) 2007-08-30
JP2008115184A (ja) 2008-05-22
PT907631E (pt) 2003-10-31
AU731146C (en) 2005-02-03
DK0907631T3 (da) 2003-09-22
ES2326004T3 (es) 2009-09-28

Similar Documents

Publication Publication Date Title
TW561150B (en) Inorganic ion receptor-modulating compounds and pharmaceutical composition comprising them
Kondo et al. β-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species
Xiang et al. Insulin resistance and impaired functional vasodilation in obese Zucker rats
Lee et al. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms
RS50997B (sr) Kompozicije 5ht2c receptor modulatora i postupci njihove upotrebe
EA023472B1 (ru) Агенты, связывающиеся с ядерными рецепторами
US8759364B2 (en) Methods of treating bone mass diseases
Santofimia-Castaño et al. Melatonin induces calcium mobilization and influences cell proliferation independently of MT1/MT2 receptor activation in rat pancreatic stellate cells
WO2017034997A1 (en) Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
EP3906027A1 (en) Methods and formulations to treat mitochondrial dysfunction
US6849654B2 (en) 5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivates thereof
Wang et al. Bcl-2 maintains the mitochondrial membrane potential, but fails to affect production of reactive oxygen species and endoplasmic reticulum stress, in sodium palmitate-induced β-cell death
Zhang et al. Chloroquine differentially modulates coronary vasodilation in control and diabetic mice
JP2009537626A (ja) ９−ヒドロキシエリプチシン誘導体による悪性表現型の復帰変異
CN106146372B (zh) 用于预防和治疗癌症的有机硒化合物
JP2021167279A (ja) ミトコンドリア病の予防または治療のための医薬組成物
WO2013148994A1 (en) Glucose transporter inhibitors
Liantonio et al. Growth hormone secretagogues exert differential effects on skeletal muscle calcium homeostasis in male rats depending on the peptidyl/nonpeptidyl structure
US20130245275A1 (en) Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides
EP3603641A1 (en) Pharmaceutical composition containing dusp1 inhibitor
EP3833354B1 (en) Tissue transglutaminase modulators for medicinal use
KR20210141933A (ko) 경계성 인격 장애의 치료 방법
Luo et al. Chrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy
JP5986098B2 (ja) インテグリン結合キナーゼ阻害剤
Guillaume Characterization of the neurokinin3-and histamine2-receptors in brown and white adipose tissue

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees